Evidence map›Paper›PMID 30854092›Full record

ArticleJournal of Cancer2019

Cadherin Related Family Member 2 Acts As A Tumor Suppressor By Inactivating AKT In Human Hepatocellular Carcinoma.

Ziyuan Xia, Meijin Huang, Qiangqiang Zhu, Yinghua Li, Qian Ma, Yang Wang, Xia Chen, Jianzhong Li, Lei Qiu, Junping Zhang and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of Cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Human mutation · 2026
    Article
  3. Article
  4. [Overexpression of CDHR2 inhibits proliferation of breast cancer cells by inhibiting the PI3K/Akt pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Ziyuan XiaDepartment of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai, China.
Meijin HuangDepartment of Oncology, 920th Hospital of PLA Joint Logistics support Force, Yunnan, China.
Qiangqiang ZhuDepartment of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai, China.
Yinghua LiDepartment of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai, China.
Qian MaDepartment of Pathology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Yang WangDepartment of Pathology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Xia ChenYangpu Hospital, Tongji University School of Medicine, Shanghai, China.
Jianzhong LiDepartment of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai, China.
Lei QiuDepartment of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai, China.
Junping ZhangDepartment of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai, China.
Jiaoyang ZhengDepartment of Endocrinology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Bin LuDepartment of Biochemical Pharmacy, School of Pharmacy, Second Military Medical University, Shanghai, China.
Second Military Medical University · CNChanghai Hospital · CNShanghai University of Traditional Chinese Medicine · CNYangpu Hospital of Tongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cadherin related family member 2 (CDHR2) belongs to the protocadherin family and is abundant in normal liver, kidney, and colon tissues, but weakly expressed in cancers arising from these tissues. In this study, we demonstrated that CDHR2 was highly expressed in para-cancer tissues of human hepatocellular carcinoma (HCC), but significantly downregulated or silenced in 85.7% (6/7) of HCC cell lines by both semi-quantitative PCR and western blot, and 79.1% (19/24) and 80.2% (89/111) of tumor tissues from patients with HCC by semi-quantitative PCR, and immunohistochemistry, respectively. Interestingly, CpG islands in the promoter of CDHR2 gene were hypermethylated in HCC cell lines and tissues compared with the para-cancer tissues by methylation-specific PCR analysis, leading to transcriptional repression and silencing of CDHR2 in HCC. In addition, CDHR2 overexpression by lentiviral vectors had suppressive effects on HCC cell growth and proliferation, as evidenced by prolonged cell doubling time and reduced colony-forming ability

Indexed as

AKTCDHR2COX2hepatocarcinomamethylationproliferation

Identifiers

PMID30854092
PMCPMC6400803
OpenAlexW2912088944

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.